Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients (PRESERVE)

2. november 2026 oppdatert av: Swedish Orphan Biovitrum

A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis

To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients

Studieoversikt

Detaljert beskrivelse

The PRESERVE study is a Phase 3b, multicenter, single-arm, open-label clinical trial designed to explore the efficacy and safety of pegcetacoplan in preventing or delaying the recurrence of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) following kidney transplantation. Recurrence of these diseases after transplantation is common and can lead to graft dysfunction and loss. Pegcetacoplan is a complement C3/C3b inhibitor that has demonstrated activity in patients with native kidney disease and recurrent disease after transplantation. The study aims to assess whether initiating pegcetacoplan at the time of kidney transplantation, before recurrence occurs, may delay the recurrence and support long-term graft outcomes. Participants will receive pegcetacoplan in addition to standard post-transplant care and will be followed to evaluate disease recurrence, kidney function, graft outcomes, safety, and tolerability.

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Pernambuco
      • Recife, Pernambuco, Brasil, 52010-010
        • Real Hospital Português
    • São Paulo
      • Botucatu, São Paulo, Brasil, 18618-970
        • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
      • São Paulo, São Paulo, Brasil, 05403-000
        • Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2R7
        • University of Alberta - Faculty of Medicine & Dentistry
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 1Y6
        • St. Paul's Hospital
    • Ontario
      • London, Ontario, Canada, N6A 5A5
        • London Health Sciences Centre (LHSC) - University Hospital
      • Toronto, Ontario, Canada, M5G 2C4
        • Toronto General Hospital
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • McGill University Health Centre Research Institute
      • Helsinki, Finland, 290
        • Helsinki University Central Hospital
    • Bas Rhin
      • Strasbourg, Bas Rhin, Frankrike, 67091
        • CHU Strasbourg - Nouvel Hôpital Civil
    • Haute Garonne
      • Toulouse, Haute Garonne, Frankrike, 31059
        • Hopital Rangueil
    • Herault
      • Montpellier, Herault, Frankrike, 34000
        • Hopital Lapeyronie pt
    • Nord
      • Lille, Nord, Frankrike, 59037
        • Hopital Claude Huriez - CHU Lille
    • Paris
      • Paris, Paris, Frankrike, 75015
        • Hôpital Necker - Enfants Malades
    • Rhone
      • Lyon, Rhone, Frankrike, 69437
        • Hopital Edouard Herriot - CHU Lyon
    • Bari
      • Bari, Bari, Italia, 70124
        • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
    • Bergamo
      • Bergamo, Bergamo, Italia, 24127
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
    • Roma
      • Roma, Roma, Italia, 165
        • Ospedale Pediatrico Bambino Gesù
      • Roma, Roma, Italia, 168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      • Riyadh, Saudi-Arabia, 11211
        • King Faisal Specialist Hospital & Research Center
    • Barcelona
      • Barcelona, Barcelona, Spania, 8035
        • Hospital Universitari Vall d'Hebron - VHIR
    • La Coruña
      • A Coruña, La Coruña, Spania, 15006
        • Complejo Hospitalario Universitario A Coruña
    • Madrid
      • Madrid, Madrid, Spania, 28041
        • Hospital Universitario 12 de Octubre
    • Málaga
      • Málaga, Málaga, Spania, 29010
        • Hospital Regional Universitario de Malaga
    • Vizcaya
      • Barakaldo, Vizcaya, Spania, 48903
        • Hospital de Cruces
    • Greater London
      • London, Greater London, Storbritannia, NW3 2QG
        • Royal Free Hospital
      • London, Greater London, Storbritannia, W12 0HS
        • Hammersmith Hospital
    • Greater Manchester
      • Manchester, Greater Manchester, Storbritannia, M13 9WL
        • Manchester Royal Infirmary
    • Tyne & Wear
      • Newcastle upon Tyne, Tyne & Wear, Storbritannia, NE7 7DN
        • Freeman Hospital
      • Lausanne, Sveits, 1011
        • Centre Hospitalier Universitaire Vaudois (CHUV)
    • Lower Saxony
      • Hanover, Lower Saxony, Tyskland, 30625
        • Medizinische Hochschule Hannover
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Tyskland, 50937
        • Universitaetsklinikum Koeln
      • Essen, North Rhine-Westphalia, Tyskland, 45147
        • Universitaetsklinikum Essen

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female patients with a diagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) who are planning to undergo kidney transplantation because of the disease.
  • Have a high risk of disease recurrence following kidney transplantation, based on either having a previous kidney allograft loss due to recurrence of C3G or primary IC-MPGN, or assessed as having a high risk by the investigator based on other clinical information.
  • Is fully vaccinated and up to date with their vaccinations against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B, in accordance with local guidelines, at the time of initiating pegcetacoplan.

Exclusion Criteria:

  • A known secondary cause for MPGN, including but not limited to monoclonal gammopathy of clinical significance, hepatitis B, hepatitis C, or autoimmune cryoglobulinemia.
  • History of invasive meningococcal disease.
  • History of malignancy, except for the following: cured basal or squamous cell skin cancer, curatively treated in situ disease, or currently malignancy-free and has been off-treatment for the malignancy for at least 5 years.
  • Hypersensitivity to pegcetacoplan or any of its excipients.
  • Known or suspected hereditary fructose intolerance.
  • Any other medical condition which, in the opinion of the Investigator, makes the participant unsuitable for inclusion.
  • Use of a complement inhibitor for the treatment of C3G or primary IC-MPGN within 1 month prior to the scheduled kidney transplantation surgery.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Pegcetacoplan

Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN

Dose amount based on age and weight Subcutaneous infusion twice-a-week. Adult participants aged 18 years or older at enrolment: 1080 mg

Adolescent participants aged 12 to 17 years at enrolment:

  • Weight ≥50 kg: 1080 mg
  • Weight 35 to <50 kg: 648 mg 1st dose, then 810 mg subsequently
  • Weight 30 to <35 kg: 540 mg for the first 2 doses, then 648 mg subsequently
Andre navn:
  • APL-2
  • Aspaveli
  • Empaveli

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Occurrence of Clinically Significant Recurrent Disease
Tidsramme: Within 2 years after kidney transplantation

Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy

Within 2 years after kidney transplantation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time to Onset of Clinically Significant Disease Recurrence
Tidsramme: Up to 2 years after kidney transplantation

To explore the impact of pegcetacoplan on time to clinically significant recurrence of C3G or primary IC-MPGN after kidney transplantation

Up to 2 years after kidney transplantation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Study Physician, Swedish Orphan Biovitrum AB (publ)

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

21. januar 2027

Primær fullføring (Antatt)

17. januar 2031

Studiet fullført (Antatt)

17. januar 2031

Datoer for studieregistrering

Først innsendt

21. oktober 2026

Først innsendt som oppfylte QC-kriteriene

21. oktober 2026

Først lagt ut (Faktiske)

27. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • Sobi.PEGCET-404
  • 2026-526392-39-00 (Ctis)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to patient level data and related study documents.

All requests are evaluated by a cross functional panel of experts within Sobi. Patient level data will be anonymized and study documents, if applicable, will be redacted to protect the privacy of trial participants.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere